Merrimack
Founded 2000
Cambridge, United States
63 employees
Post Ipo Debt
Total: $432.01M
Biotechnology, Health Care +1
Cambridge, United States
63 employees
Post Ipo Debt
Total: $432.01M
Biotechnology, Health Care +1
General Information
Get notified when Merrimack moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Merrimack
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biotechnology
About Merrimack
Funding Rounds & Investors (15)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | •••••• | 1 |
|
02 Jul 2018 |
| Post-IPO Equity | •••••• | - | 15 Dec 2017 | |
| Convertible Note | •••••• | - | 14 Apr 2016 | |
| Post-IPO Equity | •••••• | - | 13 Jul 2015 | |
| Private Equity Round | •••••• | 5 |
|
14 Apr 2011 |
Merrimack Alternatives & Competitors
Merrimack vs
Notable
United States
Notable is a mission-driven company transforming the way cancer is treated
Unknown
33 employees
Biotechnology, Health Care
Merrimack vs
Surface Oncology Inc.
United States
#lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2022,2021
Post Ipo Equity
14 employees
Biotechnology, Health Care
Merrimack vs
Rexahn Pharmaceuticals
United States
TARGETING DIFFICULT TO TREAT CANCERS
Post Ipo Equity
7 employees
Biotechnology, Medical Devices
FAQ About Merrimack
Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Its mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding...
Merrimack was founded in 2000.
Merrimack is headquartered in Cambridge, United States.
Merrimack operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Merrimack has approximately 63 employees.
Merrimack has completed 15 funding rounds, raising a total of $432.01M. The latest funding stage is Post Ipo Debt.
Top alternatives and competitors to Merrimack include Notable, Surface Oncology Inc., Rexahn Pharmaceuticals, BIOMUNEX PHARMACEUTICALS, Camino Pharma, LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Merrimack and Notable are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Don't just browse. Track.
Signal Tracker monitors Merrimack and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.